Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BT1718
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Cancer Research UK
Deal Size : Inapplicable
Deal Type : Inapplicable
BT1718 in Patients with Advanced Solid Tumours.
Details : BT1718 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 03, 2018
Lead Product(s) : BT1718
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Cancer Research UK
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
